老虎证券

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
06/20
BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

June 20 (Reuters) - EMA's CHMP:

  • POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS

  • NINTEDANIB VIATRIS GOT POSITIVE OPINION FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES

  • RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZDIFFRA, FOR TREATMENT OF ADULTS WITH NONCIRRHOTIC MASH

  • RECOMMENDED GRANTING MARKETING AUTHORISATION FOR AUSTEDO FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE TARDIVE DYSKINESIA

  • POSITIVE OPINION FOR TENOFOVIR ALAFENAMIDE FOR TREATMENT OF ADULTS AND ADOLESCENTS INFECTED WITH HIV-1

  • STARTED RE-EXAMINATION OF ITS MARCH 2025 RECOMMENDATION NOT TO GRANT A MARKETING AUTHORISATION FOR KISUNLA ON JUNE 2

Source text: [ID:]

Further company coverage: SWTX.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10